Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Now Rated "Hold" by Wall Street Brokerages

Key Points

• LKFT has a consensus “Hold” rating from eight analysts: five recommend holding and three recommend buying. The average 12-month price target is $35.50, with individual targets ranging from $26 to $45.
• Shares opened at $31.65, up 0.8%, with a market capitalization of approximately $2.09 billion. The stock has traded between $25.68 and $36.24 over the past year.
• The company reported quarterly EPS of $0.03, beating the consensus estimate of a $0.97 loss, while revenue of $15.47 million exceeded expectations of $7.29 million. Institutional investors and hedge funds own 32.46% of the stock.

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT - Get Free Report) have received a consensus recommendation of "Hold" from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $35.50.

A number of analysts have issued reports on LKFT shares. TD Cowen assumed coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Friday, August 21st. They set a "buy" rating on the stock. Weiss Ratings raised shares of Lakefront Biotherapeutics American Depositary Shares from a "hold (c-)" rating to a "hold (c)" rating in a research note on Friday, October 2nd. Morgan Stanley began coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Tuesday, October 20th. They issued an "equal weight" rating and a $26.00 price objective for the company. Royal Bank Of Canada upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a "sector perform" rating to an "outperform" rating and lifted their price objective for the company from $26.00 to $45.00 in a report on Wednesday, September 23rd. Finally, UBS Group raised shares of Lakefront Biotherapeutics American Depositary Shares to a "buy" rating in a research note on Wednesday, September 23rd.

Hedge Funds Weigh In On Lakefront Biotherapeutics American Depositary Shares

Several institutional investors have recently modified their holdings of the business. QRG Capital Management Inc. increased its position in shares of Lakefront Biotherapeutics American Depositary Shares by 21.9% during the first quarter. QRG Capital Management Inc. now owns 19,705 shares of the biotechnology company's stock worth $591,000 after acquiring an additional 3,535 shares during the period. ABC Arbitrage SA purchased a new position in Lakefront Biotherapeutics American Depositary Shares in the first quarter valued at $382,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in Lakefront Biotherapeutics American Depositary Shares in the first quarter valued at $248,000. Institutional investors and hedge funds own 32.46% of the company's stock.

Lakefront Biotherapeutics American Depositary Shares Trading Up 0.8%

LKFT stock opened at $31.65 on Friday. The company has a market capitalization of $2.09 billion, a PE ratio of -22.45 and a beta of 0.24. Lakefront Biotherapeutics American Depositary Shares has a 12-month low of $25.68 and a 12-month high of $36.24. The business's fifty day moving average price is $29.12 and its 200 day moving average price is $28.67.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT - Get Free Report) last announced its earnings results on Monday, August 10th. The biotechnology company reported $0.03 EPS for the quarter, beating analysts' consensus estimates of ($0.97) by $1.00. The firm had revenue of $15.47 million for the quarter, compared to analysts' expectations of $7.29 million. Research analysts predict that Lakefront Biotherapeutics American Depositary Shares will post -1.26 EPS for the current fiscal year.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.